摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl 2-(5-chloro-1,3-dihydroisobenzofuran-1-yl)acetate | 556108-19-1

中文名称
——
中文别名
——
英文名称
ethyl 2-(5-chloro-1,3-dihydroisobenzofuran-1-yl)acetate
英文别名
ethyl (5-chloro-1,3-dihydro-2-benzofuran-1-yl)acetate;Ethyl (5-chloro-1,3-dihydro-2-benzofuran-1-yl)acetate;ethyl 2-(5-chloro-1,3-dihydro-2-benzofuran-1-yl)acetate
ethyl 2-(5-chloro-1,3-dihydroisobenzofuran-1-yl)acetate化学式
CAS
556108-19-1
化学式
C12H13ClO3
mdl
——
分子量
240.686
InChiKey
FLBWGGNZUBHLIA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    16
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    35.5
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    ethyl 2-(5-chloro-1,3-dihydroisobenzofuran-1-yl)acetate咪唑 、 sodium tetrahydroborate 、 二异丁基氢化铝 作用下, 以 四氢呋喃甲醇二氯甲烷 为溶剂, 生成 tert-butyl-[2-(5-chloro-1,3-dihydro-2-benzofuran-1-yl)ethoxy]dimethylsilane
    参考文献:
    名称:
    Naphthyl piperazines with dual activity as 5-HT1D antagonists and 5-HT reuptake inhibitors
    摘要:
    SAR around a known molecule with dual 5-HT1D antagonist and 5-HTtransporter inhibitory activity has led to the discovery of molecules with improved dual activity and reduced cross-reactivity toward other aminergic receptors (5-HT1 beta, alpha(1), and D-2). (c) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2007.03.101
  • 作为产物:
    参考文献:
    名称:
    Naphthyl piperazines with dual activity as 5-HT1D antagonists and 5-HT reuptake inhibitors
    摘要:
    SAR around a known molecule with dual 5-HT1D antagonist and 5-HTtransporter inhibitory activity has led to the discovery of molecules with improved dual activity and reduced cross-reactivity toward other aminergic receptors (5-HT1 beta, alpha(1), and D-2). (c) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2007.03.101
点击查看最新优质反应信息

文献信息

  • Pharmaceutical compounds
    申请人:——
    公开号:US20040122001A1
    公开(公告)日:2004-06-24
    This invention relates to compounds of formula (I) where R 1 to R 12 , —W—V—, —X—Y—, m and n have the values defined in claim 1, their preparation and use as pharmaceuticals. 1
    这项发明涉及到式(I)的化合物,其中R1至R12,—W—V—,—X—Y—,m和n的值如权利要求1中定义的,它们的制备和用作药物。
  • Site‐Selective Functionalization of (sp <sup>3</sup> )C−H Bonds Catalyzed by Artificial Metalloenzymes Containing an Iridium‐Porphyrin Cofactor
    作者:Yang Gu、Sean N. Natoli、Zhennan Liu、Douglas S. Clark、John F. Hartwig
    DOI:10.1002/anie.201907460
    日期:2019.9.23
    cofactor. The generated systems catalyze the insertion of carbenes into the C-H bonds of a range of phthalan derivatives containing substituents that render the two methylene positions in each phthalan inequivalent. These reactions occur with site-selectivity ratios of up to 17.8:1 and, in most cases, with pairs of enzyme mutants that preferentially form each of the two constitutional isomers. This
    在几乎相同的空间和电子环境中,一个CH键相对于另一个CH键的选择性功能化可以促进复杂分子的构建。我们报告的CH键的站点选择性功能化,仅由远程取代基区别开来,由可进化的P450支架和铱-卟啉辅因子的组合产生的人工金属酶(ArMs)催化。所生成的系统催化将卡宾插入到一系列包含取代基的邻苯二甲酸衍生物的CH键中,这些取代基使得每个邻苯二甲酸酯中的两个亚甲基位置不等价。这些反应以高达17.8:1的位点选择性比率发生,并且在大多数情况下,是由优先形成两种结构异构体中的每一个的成对酶突变体发生的。
  • Isochroman compounds for treatment of cns disorders
    申请人:Agejas-Chicharro Javier
    公开号:US20050014750A1
    公开(公告)日:2005-01-20
    This invention relates to compounds of formula (I) where R1 to R12, —W—V—, —X—Y—, p and n have the values defined in claim 1, their preparation and use as pharmaceuticals.
    本发明涉及公式(I)的化合物,其中R1到R12,-W-V-,-X-Y-,p和n具有权利要求1中定义的值,它们的制备和用作药物。
  • Isochroman compounds for treatment of CNS disorders
    申请人:Eli Lilly and Company
    公开号:US07335660B2
    公开(公告)日:2008-02-26
    This invention relates to compounds of formula (I) where R1 to R12, —W—V—, —X—Y—, p and n have the values defined in claim 1, their preparation and use as pharmaceuticals for the treatment of central nervous system disorders, such as depression, bipolar disorder, and anxiety.
    本发明涉及公式(I)的化合物,其中R1至R12,-W-V-,-X-Y-,p和n具有声明1中定义的值,以及它们的制备和用作药物治疗中枢神经系统疾病,如抑郁症、双相情感障碍和焦虑症。
  • Assembly and Evolution of Artificial Metalloenzymes within <i>E. coli</i> Nissle 1917 for Enantioselective and Site-Selective Functionalization of C─H and C═C Bonds
    作者:Zhennan Liu、Jing Huang、Yang Gu、Douglas S. Clark、Aindrila Mukhopadhyay、Jay D. Keasling、John F. Hartwig
    DOI:10.1021/jacs.1c10975
    日期:2022.1.19
查看更多